Last update April 27, 2024

Eprosartan Mesylate

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Eprosartan is an angiotensin II receptor antagonist with actions similar to those of losartan. It is indicated in the treatment of hypertension. Oral administration once or twice a day.

At latest update, relevant published data on excretion into breast milk were not found. A high protein-binding capacity makes excretion into breast milk unlikely.

In addition, a low oral bioavailability makes difficult the absorption towards the infant's plasma from ingested milk, except in prematures or newborns who may show an increased absorption.

Until more data on this medication is available, safer alternative drugs are preferred (Rowe 2013), especially in premature babies or during the neonatal period.


Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Eprosartan Mesylate in other languages or writings:


Main tradenames from several countries containing Eprosartan Mesylate in its composition:


Variable Value Unit
Oral Bioavail. 13 - 15 %
Molecular weight 521 daltons
Protein Binding 98 %
VD 0.18 l/Kg
Tmax 1 - 2 hours
5 - 9 hours


  1. MHRA. Eprosartan. Drug Summary. 2014 Full text (in our servers)
  2. Rowe H, Baker T, Hale TW. Maternal medication, drug use, and breastfeeding. Pediatr Clin North Am. 2013 Feb;60(1):275-94. Abstract
  3. AEMPS. Eprosartán. Ficha técnica. 2012 Full text (in our servers)
  4. Tamargo j, Caballero R, Gómez R, Núñez L, Vaquero M y Delpón E. Características farmacológicas de los ARA-II. ¿Son todos iguales?. Rev Esp Cardiol Supl. 2006;6:10C-24C. 2006 Full text (in our servers)

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM